184 related articles for article (PubMed ID: 22225546)
1. Patient preferences for psoriasis treatments: impact of treatment experience.
Schaarschmidt ML; Umar N; Schmieder A; Terris DD; Goebeler M; Goerdt S; Peitsch WK
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):187-98. PubMed ID: 22225546
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK
Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115
[TBL] [Abstract][Full Text] [Related]
3. Comorbidities significantly impact patients' preferences for psoriasis treatments.
Schmieder A; Schaarschmidt ML; Umar N; Terris DD; Goebeler M; Goerdt S; Peitsch WK
J Am Acad Dermatol; 2012 Sep; 67(3):363-72. PubMed ID: 22015150
[TBL] [Abstract][Full Text] [Related]
4. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.
Kromer C; Schaarschmidt ML; Schmieder A; Herr R; Goerdt S; Peitsch WK
PLoS One; 2015; 10(6):e0129120. PubMed ID: 26058083
[TBL] [Abstract][Full Text] [Related]
5. Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.
Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Sonntag D; Goerdt S; Peitsch WK
PLoS One; 2015; 10(12):e0144335. PubMed ID: 26633680
[TBL] [Abstract][Full Text] [Related]
6. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.
Kromer C; Peitsch WK; Herr R; Schmieder A; Sonntag D; Schaarschmidt ML
J Dtsch Dermatol Ges; 2017 Feb; 15(2):189-200. PubMed ID: 28214326
[TBL] [Abstract][Full Text] [Related]
7. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.
Florek AG; Wang CJ; Armstrong AW
Arch Dermatol Res; 2018 May; 310(4):271-319. PubMed ID: 29442137
[TBL] [Abstract][Full Text] [Related]
8. Satisfaction with treatment among patients with psoriasis: a web-based survey study.
van Cranenburgh OD; de Korte J; Sprangers MA; de Rie MA; Smets EM
Br J Dermatol; 2013 Aug; 169(2):398-405. PubMed ID: 23565643
[TBL] [Abstract][Full Text] [Related]
9. Clearance of psoriasis: the impact of private versus public insurance.
Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
11. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
Lecha M; Mirada A; López S; Artés M;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
[TBL] [Abstract][Full Text] [Related]
13. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences for topical psoriasis treatments: a discrete choice experiment.
Hoelker S; Ninosu N; Buettner S; Peitsch WK; Schaarschmidt ML
J Dermatolog Treat; 2022 Aug; 33(5):2595-2604. PubMed ID: 35373695
[TBL] [Abstract][Full Text] [Related]
15. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y
J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814
[TBL] [Abstract][Full Text] [Related]
17. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
Radtke MA; Schäfer I; Blome C; Augustin M
Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
[TBL] [Abstract][Full Text] [Related]
18. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis.
Seston EM; Ashcroft DM; Griffiths CE
Arch Dermatol; 2007 Sep; 143(9):1175-9. PubMed ID: 17875880
[TBL] [Abstract][Full Text] [Related]
19. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
Feldman SR; Evans C; Russell MW
J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
